Ferrer enters into a collaboration and license agreement with Prilenia

Barcelona (Spain), April 28th, 2025. Together with Prilenia Therapeutics B.V., a clinical-stage biotech company, Ferrer have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region.

Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previous clinical studies. These investigational studies demonstrate that at the therapeutic dose, Pridopidine has an observed safety and tolerability profile comparable to placebo.

Pridopidine is currently being reviewed by the European Medicines Agency, which has accepted the Marketing Authorisation Application submission for the treatment of HD. An opinion from the Committee for Medicinal Products for Human Use is expected in the second half of 2025. The terms of the agreement include an upfront payment and multiple regulatory, development, commercial and sales milestone payments. Prilenia will also receive tiered double-digit royalties on net sales of Pridopidine.